Trial Profile
Phase I Clinical and Pharmacokinetic Study to Determine the Safety of Ecteinascidin-743 Administered as a Single Intravenous Infusion Over 60 Minutes Every 21 Days in Patients with Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jul 2012 New trial record